Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection

Bamlanivimab and etesevimab are neutralizing antibodies indicated for treatment of coronavirus disease 2019 (COVID‐19) in patients with early mild or moderate disease. We present the use of pharmacokinetic/pharmacodynamic (PK/PD) modeling that characterizes the timecourse of viral load obtained from...

Descripción completa

Detalles Bibliográficos
Autores principales: Chigutsa, Emmanuel, O’Brien, Lisa, Ferguson‐Sells, Lisa, Long, Amanda, Chien, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652670/
https://www.ncbi.nlm.nih.gov/pubmed/34514598
http://dx.doi.org/10.1002/cpt.2420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652670/
https://www.ncbi.nlm.nih.gov/pubmed/34514598
http://dx.doi.org/10.1002/cpt.2420

Ejemplares similares